Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 4;72(1):23–37. doi: 10.1007/s00262-022-03221-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — A Kaplan–Meier analysis showed that patients with a higher BICS exhibited a worse OS in the ICI cohort. B Time-dependent ROC curve at 0.5-, 1-, and 2-year OS for BICS in the ICI cohort (0.5-year AUC = 0.657, 1-year AUC = 0.701, and 2-year AUC = 0.746). C OS from the start of therapy stratified by BICS in patients in the ICI cohort treated with PD-1 single-agent blockade, PD-1 and chemotherapy combination therapy, or a combination of PD-1 and targeted therapy. D Clustered heatmap showing the four immune-related PBIMs that classify patients (represented in columns) into DCB or NDB groups. BICS: peripheral-blood-immune-cell-based signature; ICIs: immune checkpoint inhibitors; AUC: area under the curve; PD-1: programmed death 1; PD-L1: programmed death 1 ligand; DCB: durable clinical outcomes; NDB: no durable benefit; RCC: renal cell carcinoma; ESCC: esophageal squamous cell carcinoma; GAC: gastric adenocarcinoma; SCLC: small-cell lung cancer; NSCLC: non-small cell lung cancer; HCC: hepatocellular carcinoma